The global rise in antibiotic resistance threatens infection prevention and cure
May 20, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing antibiotic resistance, antimicrobial resistance, feature, pharma
Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic …
AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit
May 20, 2019Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure
AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke
May 20, 2019Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure
Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …
Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show
May 20, 2019Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis
Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …
Sandoz is first multinational to secure generic approval under new Chinese guidelines
May 20, 2019Sales and Marketing China, Novartis, Sandoz, generics, pharma, rosuvastatin
Sandoz has revealed that its generic statin rosuvastatin, known in its branded incarnation as Crestor, has been given approval in …
NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma
May 20, 2019Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma
Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …
Phase 1/2 data show Roche’s entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents
May 17, 2019Medical Communications, Research and Development Cancer, Roche, entrectinib, pharma
Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent …
Top Ten most popular articles on Pharmafile.com this week!
May 17, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics
Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
Pfizer’s Fragmin injection secures FDA approval in paediatric symptomatic venous thromboembolism
May 17, 2019Medical Communications, Sales and Marketing FDA, Fragmin, Pfizer, pharma
The FDA has announced its approval of Pfizer’s anticoagulant injection Fragmin (dalteparin sodium) for subcutaneous use as a treatment to …
Gilead CEO Daniel O’Day challenged over patents on PrEP drug Truvada
May 17, 2019Medical Communications Gilead, HIV, PrEP, Truvada, patent, pharma
On 16 May, Gilead CEO Daniel O’Day was grilled over the $1,780 price tag on PrEP drug Truvada in a …
Twitter launches new initiative to direct users towards credible information on vaccines
May 17, 2019Medical Communications Twitter, anti-vaccine, health, pharma, social media, vaccines
Twitter will now present users with a pinned tweet directing them towards reliable information on vaccines, according to a blog …
A day in the life: Lance Hill, CEO at Within3
May 17, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing A day in the life, Interview, Within3, feature
Could you give a short history of how you came to be in your current role? I’ve spent my entire …
Insider Interview: Paving paths in prostate cancer
May 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer
Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …
Pfizer’s abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis
May 16, 2019Research and Development Pfizer, abrocitinib, atopic dermatitis, pharma
Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that …
ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial
May 16, 2019Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks
Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …
FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia
May 16, 2019Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma
Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …
Novartis’ Kymriah to be covered by Japan’s national insurance system
May 16, 2019Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma
Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …
J&J to invest €100 million into Limerick manufacturing facilities creating 100 new jobs
May 16, 2019Manufacturing and Production Ireland, J&J, JJ, Limerick, medical technology, pharma
Healthcare conglomerate Johnson & Johnson has said it will be investing €100 million into the expansion of its Vision Care …
EUSA Pharma bolsters senior leadership team with two appointments
May 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eusa Pharma, appointment
Rare disease and oncology biopharma firm EUSA Pharma has revealed two new additions to its senior leadership team in two …
Paola Chiesi awarded honorary doctorate by Karolinska Institutet
May 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Paolo Chiesi, Vice President of the Chiesi Group, has been made an Honorary Doctor at the Karolinska Institutet – a …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
